“If this blog helped you out, don’t keep it to yourself—share the link on your socials!” 👍 “Like what you read? Spread the love and share this blog on your social media.” 👍 “Found this useful? Hit share and let your friends know too!” 👍 “If you enjoyed this post, please share the URL with your friends online.” 👍 “Sharing is caring—drop this link on your social media if it helped you.”

Saturday, August 30, 2025

Ardelyx


Ardelyx products


 IBSRELA (tenapanor)

Indication: Treatment of irritable bowel syndrome with constipation (IBS-C) in adults
Status: FDA-approved in the U.S.; also marketed in Canada

XPHOZAH (tenapanor)
Indication: Reduction of serum phosphate in adults with chronic kidney disease (CKD) on dialysis, as add-on therapy for patients intolerant or unresponsive to phosphate binders
Status: FDA-approved in the U.S.

PHOZEVEL (tenapanor)
Indication: Hyperphosphatemia in CKD patients on dialysis
Status: Approved and launched in Japan

Wan Ti Le (tenapanor)
Indication: Hyperphosphatemia management in adult dialysis patients
Status: Approved in China; marketed under this local brand name via licensing partner



on

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)